BNP Paribas Financial Markets Has $289,000 Position in Harrow, Inc. (NASDAQ:HROW)

BNP Paribas Financial Markets cut its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,628 shares of the company's stock after selling 71,346 shares during the quarter. BNP Paribas Financial Markets' holdings in Harrow were worth $289,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Woodmont Investment Counsel LLC increased its stake in shares of Harrow by 0.5% in the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock worth $2,731,000 after buying an additional 445 shares during the last quarter. Swiss National Bank lifted its holdings in Harrow by 1.0% in the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock valued at $1,990,000 after acquiring an additional 600 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after acquiring an additional 727 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Harrow by 5.7% during the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock worth $634,000 after buying an additional 1,026 shares during the period. Finally, HighTower Advisors LLC raised its holdings in Harrow by 13.8% during the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock worth $340,000 after buying an additional 1,227 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Performance

Harrow stock traded up $1.28 during trading hours on Thursday, reaching $27.20. 384,121 shares of the company were exchanged, compared to its average volume of 496,299. The firm has a market cap of $997.83 million, a price-to-earnings ratio of -28.94 and a beta of 0.41. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a 50-day moving average of $25.19 and a 200 day moving average of $30.69. Harrow, Inc. has a 12 month low of $16.71 and a 12 month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. As a group, research analysts anticipate that Harrow, Inc. will post -0.53 earnings per share for the current year.

Analysts Set New Price Targets

HROW has been the topic of a number of research reports. HC Wainwright increased their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th. B. Riley reduced their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.